Animal diseases

Meeting Preview: Hot Topics At NUTRITION 2021 LIVE ONLINE

Retrieved on: 
Tuesday, May 18, 2021

b'BETHESDA, Md., May 18, 2021 /PRNewswire/ -- Reporters and bloggers are invited to join top nutrition researchers and practitioners for a dynamic virtual program at NUTRITION 2021 LIVE ONLINE .

Key Points: 
  • b'BETHESDA, Md., May 18, 2021 /PRNewswire/ -- Reporters and bloggers are invited to join top nutrition researchers and practitioners for a dynamic virtual program at NUTRITION 2021 LIVE ONLINE .
  • The flagship meeting of the American Society for Nutrition runs June 7-10, 2021 and features research announcements, expert discussions and more.\nExplore the meeting program and register for a press pass to attend .
  • Hundreds of live and recorded sessions will be available on demand for you to enjoy from the comfort of home.\nHighlights from NUTRITION 2021 LIVE ONLINE include:\nCOVID-19, Diet and the Immune System- COVID-19 has remarkably different effects from person to person.
  • In this session, leading researchers take a deep dive into the possible interactions between nutrition, the immune system and the SARS-CoV-2 virus.

Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 17, 2021

\xe2\x80\x9cAs discussed in our coronavirus update release earlier this month, we continue developing novel SARS-CoV-2 oral protease inhibitors and are rapidly advancing lead compounds.

Key Points: 
  • \xe2\x80\x9cAs discussed in our coronavirus update release earlier this month, we continue developing novel SARS-CoV-2 oral protease inhibitors and are rapidly advancing lead compounds.
  • That agreement provides Cocrystal with an exclusive, royalty-bearing license to develop and commercialize therapeutic, diagnostic and prophylactic products against coronaviruses, caliciviruses and picornaviruses based on antivirals discovered by KSURF.
  • The Company believes the 3CL protease has the ability to convert the inactive SARS-CoV-2 replication enzymes into the active form.
  • As anticipated, Cocrystal reported no revenues for the first quarter of 2021 compared with $461,000 in revenues for the first quarter of 2020.

Tevogen Bio’s TVGN-489, an Allogeneic SARS-CoV-2 Specific Cytotoxic T Cell Therapy, Demonstrates Strong Anti-Viral Activity in Preclinical Study, as Presented by Professor Neal Flomenberg of Thomas Jefferson University

Retrieved on: 
Tuesday, May 11, 2021

b'Tevogen Bio, a clinical stage biotechnology company, announced that its investigational COVID-19 therapy, TVGN-489, demonstrated strong antiviral activity against SARS-CoV-2 in the preclinical study.

Key Points: 
  • b'Tevogen Bio, a clinical stage biotechnology company, announced that its investigational COVID-19 therapy, TVGN-489, demonstrated strong antiviral activity against SARS-CoV-2 in the preclinical study.
  • COVID-19 reactive cells comprised 70% or more of the cells in initial batches of this product.
  • These data suggest the viability of TVGN-489 as a potentially curative treatment for COVID-19.
  • Neal Flomenberg is the Chairman of the Department of Medical Oncology and Deputy Director of the Sidney Kimmel Cancer Center at Jefferson University in Philadelphia.

AIkido Pharma Inc. Announces First Quarter 2021 Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 11, 2021

We continue to make progress with our anti-viral platform with new compounds being tested against influenza virus and testing on SARS-CoV-2.

Key Points: 
  • We continue to make progress with our anti-viral platform with new compounds being tested against influenza virus and testing on SARS-CoV-2.
  • Furthermore, our partnerships with leading academia continues to allow us to pursue pipeline expansion opportunities in emerging and high growth technologies.
  • With approximately$102 millionin cash and cash equivalents on March 31, 2021, and approximately 89.5 million shares outstanding, the Company\'s cash per share equates to approximately $1.15 per share.
  • The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.\n'

Open Orphan plc Announces £3m COVID-19 Challenge Virus Manufacturing Contract

Retrieved on: 
Monday, May 10, 2021

These challenge agents are then used in controlled human infection studies, an area that hVIVO has focussed on since 2001.\nOpen Orphan has successfully initiated the development of a number of Coronavirus challenge viruses.

Key Points: 
  • These challenge agents are then used in controlled human infection studies, an area that hVIVO has focussed on since 2001.\nOpen Orphan has successfully initiated the development of a number of Coronavirus challenge viruses.
  • The Company has already developed the initial circulating COVID-19 (SARS-CoV-2) virus as part of the Human Challenge Programme in partnership with the UK Government.\nCathal Friel, Executive Chairman of Open Orphan plc commented: \xe2\x80\x9cThis contract is a great example of how our unique abilities to provide an all encompassing solution for human challenge trials sets us apart.
  • Production of a SARS-CoV-2 variant challenge virus builds upon our knowledge and learnings from manufacturing and characterising the original Wuhan-like D614G SARS-CoV-2 virus.
  • Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD.

Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights

Retrieved on: 
Monday, May 10, 2021

\xe2\x80\x9cSpecifically, we continue to advance MAT2203 in cryptococcal meningitis through Cohort 2 of the EnACT trial towards its next DSMB review, which is anticipated in the third quarter of 2021.

Key Points: 
  • \xe2\x80\x9cSpecifically, we continue to advance MAT2203 in cryptococcal meningitis through Cohort 2 of the EnACT trial towards its next DSMB review, which is anticipated in the third quarter of 2021.
  • These results are identical to those of the first quarter of 2020.\nResearch and development expenses for the first quarter of 2021 were $3.2 million, compared to $4.1 million for the same period in 2020.
  • These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements.
  • Matinas BioPharma\xe2\x80\x99s product candidates are all in a development stage and are not available for sale or use.\n'

Global PCR (qPCR, dPCR, Singleplex & Multiplex) Markets Report 2021-2025 with Updated Impacts of COVID-19 Diagnostics - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021

b"Quidel Expects SARS-CoV-2 Testing Demand to Continue 'Through 2022, and Beyond'\nIsrael's Nucleix Targeting US Market With Noninvasive Bladder, Lung Cancer Assays\n"

Key Points: 

b"Quidel Expects SARS-CoV-2 Testing Demand to Continue 'Through 2022, and Beyond'\nIsrael's Nucleix Targeting US Market With Noninvasive Bladder, Lung Cancer Assays\n"

Animal Growth Enhancers Market| New Opportunities | Protection of Humans from Animal-food Related Diseases to Boost Growth in the Health Care Industry | Technavio

Retrieved on: 
Friday, May 7, 2021

The growing need to protect humans from animal-food-related diseases will be one of the significant factors that will have a positive impact on the market's growth.

Key Points: 
  • The growing need to protect humans from animal-food-related diseases will be one of the significant factors that will have a positive impact on the market's growth.
  • The administration of anti-microbial agents in animals helps to control the transmission of diseases such as zoonotic pathogens from animals to humans.
  • China,India, and Indonesia are the key markets for the animal growth enhancers market in Asia.
  • Market growth in this region will be fasterthan the growth of the market in other regions.

Animal Health Diagnostics Market| New Opportunities | Increase in Pet Humanization to Boost Growth in the Health Care Industry | Technavio

Retrieved on: 
Friday, May 7, 2021

The report also throws light on the impact of the COVID-19 pandemic on the market and the new opportunities and challenges market players can expect.

Key Points: 
  • The report also throws light on the impact of the COVID-19 pandemic on the market and the new opportunities and challenges market players can expect.
  • To prevent the transmission of zoonotic diseases, WHO implemented several initiatives such as tracking, surveillance, reporting activities, and response plan development in case of epidemics.
  • The US and Canada are the key markets for the animal health diagnostics market in North America.
  • Market growth in this region will be slowerthan the growth of the market in Asia.

GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 6, 2021

Details are provided further below.\nCapital Resources\xe2\x80\x93 On February 11, 2021, GeoVax supplemented its cash resources through a $10.3 million follow-on offering of common stock ($9.4 million net proceeds).

Key Points: 
  • Details are provided further below.\nCapital Resources\xe2\x80\x93 On February 11, 2021, GeoVax supplemented its cash resources through a $10.3 million follow-on offering of common stock ($9.4 million net proceeds).
  • SARS-CoV-2 is a type of coronavirus (a Betacoronavirus) that also causes Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
  • We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.
  • We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.\n'